Latest Market News

Brazilian Critical Minerals (ASX: BCM) has reinforced the scale and quality of its Ema rare earth project with strong drilling results and steady progress on permitting and feasibility studies, positioning it well amid tightening global supply.

Vulcan Energy has officially started full-scale construction of its Lionheart lithium chemicals facility in Frankfurt, targeting a 2028 commercial production start with a capacity to supply 500,000 EV batteries annually.

Auric Mining has appointed Gareth Solly as CEO, aiming to fast-track its transition to a mid-tier gold producer by developing the Burbanks processing facility and expanding operations at Munda.

PLS Group delivered a record 232.4kt spodumene concentrate production in March 2026, lifted revenue 52% to A$567 million on soaring lithium prices, and strengthened its balance sheet with a US$600 million senior notes issuance.

Cycliq Group’s Q3 FY2026 customer receipts fell 23% year-on-year to $561k, though a late March UpRide Birthday campaign injected $256k in revenue. Operating cash outflows reflect prior quarter cost settlements, with hopes for cost normalisation and sales momentum in Q4.

Yancoal Australia posted a record 38.6 million tonnes of attributable saleable coal in 2025, up 5% on 2024, but net profit after tax plunged 64% to A$440 million amid softer coal prices. The miner maintained disciplined cost control and declared A$769 million in fully franked dividends.

Qube Holdings Limited is set for a $9.3 billion cash takeover by a Macquarie-led consortium, with court approval granted to convene shareholder meetings in June. The scheme offers shareholders a 28% premium and is backed by an independent expert's fair and reasonable opinion.

Sandon Capital Investments has locked in $2.67 million through an institutional placement priced in line with its recent share purchase plan and dividend reinvestment plan.

Southern Hemisphere Mining has completed Phase I drilling at its Southern Porphyry target in Chile, confirming a large hydrothermal system and delivering encouraging assay results. The company is gearing up for Phase II drilling targeting the elusive high-grade core.

Pinnacle Minerals has exited its US critical minerals ventures, retaining key Australian and Canadian assets while bolstering its board and cash position to pursue strategic growth.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

N1 Holdings delivered record settlement volumes and a 127% surge in quarterly cash receipts despite challenging market conditions, driven by disciplined funding and operational efficiency.